Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
Immutep reports positive Overall Response Ratein its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers
Hemerion lève 3,5 millions € pour financer le développement de nouvelles solutions pour le traitement du glioblastome